TEVA — TEVA PHARMACEUTICAL INDUSTRIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 818686 ·
Israel
Last close
$42.62
Market Cap
$49.73B
52W High
$44.57
52W Low
$24.01
ADV30
7,318,329
Next earnings
2027-01-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 4,142,000,000 | 2,153,000,000 | 149,000,000 | -576,000,000 | 39,857,000,000 | 3,655,000,000 | 32,100,000,000 |
| Mar 2026 | 3,981,000,000 | 1,972,000,000 | 759,000,000 | 369,000,000 | 40,040,000,000 | 3,741,000,000 | 31,808,000,000 |
| Dec 2025 | 4,711,000,000 | 2,656,000,000 | 1,269,000,000 | 480,000,000 | 40,748,000,000 | 3,556,000,000 | 32,834,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,770,000,000
Investing CF
$114,000,000
Financing CF
$57,000,000
CapEx
$-580,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.43
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,736,000,000
Inventory
$3,173,000,000
Receivables
$3,837,000,000
ST Investments
—
EBIT TTM
$1,224,000,000
Pretax Income TTM
$362,000,000
Interest Exp TTM
$862,000,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,230,000,128
EBITDA
$4,405,000,192
Free Cash Flow
$1,492,000,000
Enterprise Value
$62,636,490,752
Total Cash
$4,084,999,936
Total Debt
$16,997,999,616
Shares Out
1,166,826,784
Trailing EPS
$0.43
Book Value
$6.84
ROE
6.7%
ROA
5.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,257,000,000 | 3,952,000,000 | 1,410,000,000 | 40,748,000,000 | 32,834,000,000 | 7,910,000,000 | 1,649,000,000 |
| Dec 2024 | 16,544,000,000 | 3,364,000,000 | -1,639,000,000 | 39,326,000,000 | 33,606,000,000 | 5,373,000,000 | 1,247,000,000 |
| Dec 2023 | 15,845,000,000 | 3,194,000,000 | -559,000,000 | 43,479,000,000 | 35,353,000,000 | 7,506,000,000 | 1,368,000,000 |
| Dec 2022 | 14,925,000,000 | 2,690,000,000 | -2,446,000,000 | 44,011,000,000 | 35,413,000,000 | 7,804,000,000 | 1,590,000,000 |
TTM Snapshot
Revenues TTM
$17,315,000,000
NetIncome TTM
$707,000,000
OpCashFlow TTM
—
Assets (Latest)
$39,857,000,000
Forward EPS
$3.12
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $32.00 · spot: $42.23 · call volume: 2,118 · put volume: 791
Expected Move to 2026-12-18:
±$3.05
(7.22%) —
implied range
$39.18 –
$45.28
· ATM straddle on $42.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | $43.55B | $413.26 | — |
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $69.11B | $21.64 | — |
| ZTS | Zoetis Inc. | $33.92B | $83.48 | — |
| GMAB | GENMAB A/S | $31.95B | $51.96 | — |
| RPRX | Royalty Pharma plc | $30.58B | $68.68 | — |
News headlines (Yahoo Finance, 1h cache)
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
2026-11-18 22:00 · Yahoo
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
2026-11-16 13:00 · Yahoo
AJOVY® Formally Included in China's National Reimbursement Drug List 2026
2026-11-14 13:51 · Yahoo
Teva Pharmaceutical Industries (TEVA) Holds First R&D Day With New Pipeline Milestones
2026-11-12 10:14 · Yahoo
Teva Pharmaceutical Industries (TEVA) Earnings Put Its Turnaround Valuation Back In Focus
2026-11-12 05:13 · Yahoo
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
2026-11-11 21:12 · Yahoo
Sector Update: Healthcare Stocks Softer in Afternoon Trading
2026-11-11 18:29 · Yahoo
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
2026-11-11 12:30 · Yahoo
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
2026-11-09 10:23 · Yahoo
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
2026-11-06 14:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.